On June 25, WuXi AppTec (02359.HK) rose 3.6% in regular trading, trading at HK$146.8/share, with turnover of HK$458 million. The rally follows the previous session's 8.55% surge in A-shares and reflects continued positive momentum across the CXO and innovative drug sectors.

On the news front, the company has been executing daily A-share buybacks of approximately RMB 100 million, with its cumulative RMB 1 billion buyback plan nearing completion. Additionally, the HK$2.5 billion H-share reward trust plan has been fully completed, with approximately 20.15 million shares repurchased, representing about 0.68% of total share capital. Institutional positioning has also turned favorable, with UBS increasing its H-share stake to 8.03%, while JPMorgan reduced its short position from 3.11% to 2.34%.

Within the Life Sciences Tools and Services sector, peers showed broad strength, with WuXi XDC up 4.79%, WuXi Biologics up 2.77%, and Insilico up 14.12%, signaling ongoing sector-wide sentiment recovery.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)